Based in Research Triangle Park, North Carolina, Bayer Biological Products is an international leader in the production of plasma derived products and their biotech substitutes.
Dedicated to producing novel treatments and therapies that extend and enhance the lives of individuals who are diagnosed with a variety of life-threatening diseases, Bayer BP’s portfolio of plasma products includes:
Gamimune® N/ Polyglobin® N, Immune Globulin Intravenous (Human) 10%, indicated for treating a wide variety of auto-immune disorders and primary immune deficiencies.
Prolastin®, indicated for chronic augmentation therapy of patients living with congenital pulmonary emphysema.
Kogenate® FS and KOGENATE® Bayer, recombinant factor VIII for the treatment of hemophilia A.
Bayer BP’s facilities in Raleigh and Clayton, N.C., and Berkeley, CA, support a wide range of scientific activities, including drug discovery, biotechnology and novel concepts in plasma safety. Advanced product developments and intensive research opportunities are key to continuing Bayer BP’s success.